TY - JOUR
T1 - Luxembourg Parkinson’s study -comprehensive baseline analysis of Parkinson’s disease and atypical parkinsonism
AU - Pavelka, Lukas
AU - Rawal, Rajesh
AU - Ghosh, Soumyabrata
AU - Pauly, Claire
AU - Pauly, Laure
AU - Hanff, Anne Marie
AU - Kolber, Pierre Luc
AU - Jónsdóttir, Sonja R.
AU - Mcintyre, Deborah
AU - Azaiz, Kheira
AU - Thiry, Elodie
AU - Vilasboas, Liliana
AU - Soboleva, Ekaterina
AU - Giraitis, Marijus
AU - Tsurkalenko, Olena
AU - Sapienza, Stefano
AU - Diederich, Nico
AU - Klucken, Jochen
AU - Glaab, Enrico
AU - Aguayo, Gloria A.
AU - Jubal, Eduardo Rosales
AU - Perquin, Magali
AU - Vaillant, Michel
AU - May, Patrick
AU - Gantenbein, Manon
AU - Satagopam, Venkata P.
AU - Krüger, Rejko
N1 - Publisher Copyright:
Copyright © 2023 Pavelka, Rawal, Ghosh, Pauly, Pauly, Hanff, Kolber, Jónsdóttir, Mcintyre, Azaiz, Thiry, Vilasboas, Soboleva, Giraitis, Tsurkalenko, Sapienza, Diederich, Klucken, Glaab, Aguayo, Jubal, Perquin, Vaillant, May, Gantenbein, Satagopam, Krüger and on behalf of the NCER-PD Consortium.
PY - 2023/12/19
Y1 - 2023/12/19
N2 - Background: Deep phenotyping of Parkinson’s disease (PD) is essential to investigate this fastest-growing neurodegenerative disorder. Since 2015, over 800 individuals with PD and atypical parkinsonism along with more than 800 control subjects have been recruited in the frame of the observational, monocentric, nation-wide, longitudinal-prospective Luxembourg Parkinson’s study. Objective: To profile the baseline dataset and to explore risk factors, comorbidities and clinical profiles associated with PD, atypical parkinsonism and controls. Methods: Epidemiological and clinical characteristics of all 1,648 participants divided in disease and control groups were investigated. Then, a cross-sectional group comparison was performed between the three largest groups: PD, progressive supranuclear palsy (PSP) and controls. Subsequently, multiple linear and logistic regression models were fitted adjusting for confounders. Results: The mean (SD) age at onset (AAO) of PD was 62.3 (11.8) years with 15% early onset (AAO < 50 years), mean disease duration 4.90 (5.16) years, male sex 66.5% and mean MDS-UPDRS III 35.2 (16.3). For PSP, the respective values were: 67.6 (8.2) years, all PSP with AAO > 50 years, 2.80 (2.62) years, 62.7% and 53.3 (19.5). The highest frequency of hyposmia was detected in PD followed by PSP and controls (72.9%; 53.2%; 14.7%), challenging the use of hyposmia as discriminating feature in PD vs. PSP. Alcohol abstinence was significantly higher in PD than controls (17.6 vs. 12.9%, p = 0.003). Conclusion: Luxembourg Parkinson’s study constitutes a valuable resource to strengthen the understanding of complex traits in the aforementioned neurodegenerative disorders. It corroborated several previously observed clinical profiles, and provided insight on frequency of hyposmia in PSP and dietary habits, such as alcohol abstinence in PD. Clinical trial registration: clinicaltrials.gov, NCT05266872.
AB - Background: Deep phenotyping of Parkinson’s disease (PD) is essential to investigate this fastest-growing neurodegenerative disorder. Since 2015, over 800 individuals with PD and atypical parkinsonism along with more than 800 control subjects have been recruited in the frame of the observational, monocentric, nation-wide, longitudinal-prospective Luxembourg Parkinson’s study. Objective: To profile the baseline dataset and to explore risk factors, comorbidities and clinical profiles associated with PD, atypical parkinsonism and controls. Methods: Epidemiological and clinical characteristics of all 1,648 participants divided in disease and control groups were investigated. Then, a cross-sectional group comparison was performed between the three largest groups: PD, progressive supranuclear palsy (PSP) and controls. Subsequently, multiple linear and logistic regression models were fitted adjusting for confounders. Results: The mean (SD) age at onset (AAO) of PD was 62.3 (11.8) years with 15% early onset (AAO < 50 years), mean disease duration 4.90 (5.16) years, male sex 66.5% and mean MDS-UPDRS III 35.2 (16.3). For PSP, the respective values were: 67.6 (8.2) years, all PSP with AAO > 50 years, 2.80 (2.62) years, 62.7% and 53.3 (19.5). The highest frequency of hyposmia was detected in PD followed by PSP and controls (72.9%; 53.2%; 14.7%), challenging the use of hyposmia as discriminating feature in PD vs. PSP. Alcohol abstinence was significantly higher in PD than controls (17.6 vs. 12.9%, p = 0.003). Conclusion: Luxembourg Parkinson’s study constitutes a valuable resource to strengthen the understanding of complex traits in the aforementioned neurodegenerative disorders. It corroborated several previously observed clinical profiles, and provided insight on frequency of hyposmia in PSP and dietary habits, such as alcohol abstinence in PD. Clinical trial registration: clinicaltrials.gov, NCT05266872.
KW - environment exposure
KW - hyposmia
KW - parkinsonian disorders
KW - Parkinson’s disease
KW - progressive supranuclear palsy
KW - REM-sleep behaviour disorder
UR - http://www.scopus.com/inward/record.url?scp=85181200385&partnerID=8YFLogxK
UR - https://pubmed.ncbi.nlm.nih.gov/38174101
U2 - 10.3389/fneur.2023.1330321
DO - 10.3389/fneur.2023.1330321
M3 - Article
C2 - 38174101
AN - SCOPUS:85181200385
SN - 1664-2295
VL - 14
JO - Frontiers in Neurology
JF - Frontiers in Neurology
M1 - 1330321
ER -